Loading...

We've got a brand new version of Simply Wall St! Try it out

TTY Biopharm

GTSM:4105
Snowflake Description

Flawless balance sheet with proven track record.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
4105
GTSM
NT$20B
Market Cap
  1. Home
  2. TW
  3. Pharmaceuticals & Biotech
Company description

TTY Biopharm Company Limited, together with its subsidiaries, produces various pharmaceuticals and chemical drugs in Taiwan and internationally. The last earnings update was 6 days ago. More info.


Add to Portfolio Compare Print
4105 Share Price and Events
7 Day Returns
-0.7%
GTSM:4105
-1.7%
TW Pharmaceuticals
-0.5%
TW Market
1 Year Returns
-4%
GTSM:4105
16%
TW Pharmaceuticals
17.7%
TW Market
4105 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
TTY Biopharm (4105) -0.7% 1.4% 3.4% -4% -21.7% 41%
TW Pharmaceuticals -1.7% 3.4% 3.5% 16% -10.7% -23.2%
TW Market -0.5% 2.8% 9.1% 17.7% 26.3% 26.1%
1 Year Return vs Industry and Market
  • 4105 underperformed the Pharmaceuticals industry which returned 16% over the past year.
  • 4105 underperformed the Market in Taiwan, Province of China which returned 17.7% over the past year.
Price Volatility
4105
Industry
5yr Volatility vs Market

Value

 Is TTY Biopharm undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of TTY Biopharm to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for TTY Biopharm.

GTSM:4105 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model Dividend Discount Model
Dividend Per Share Company Filings (2019-09-30) in TWD NT$ 4.15066125
Payout Ratio Company Filings (2019-09-30) 7463.4%
Discount Rate (Cost of Equity) See below 7.5%
Perpetual Growth Rate 10-Year TW Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for GTSM:4105
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year TW Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.69
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.687 (1 + (1- 20%) (10.32%))
0.794
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.8
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (0.8 * 5.96%)
7.5%

Discounted Cash Flow Calculation for GTSM:4105 using Dividend Discount Model Model

The calculations below outline how an intrinsic value for TTY Biopharm is arrived at by discounting future dividends to their present value. This approach is used for finance firms where free cash flow is difficult to estimate (e.g. Banks/ Insurance firms).

If the firm does not pay the majority of its earnings out as a dividend this method will often arrive at a value significantly lower than the share price.

See our documentation to learn about this calculation.

GTSM:4105 Gordon Growth Model
Calculation Result
Value per share = Expected dividends per share / (Discount Rate - Perpetual growth rate)
= NT$4.15 / (7.5% - 2.73%)
NT$87.05
GTSM:4105 Discount to Share Price
Calculation Result
Value per share (TWD) From above. NT$87.05
Current discount Discount to share price of NT$81.80
= -1 x (NT$81.80 - NT$87.05) / NT$87.05
6%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price TTY Biopharm is available for.
Intrinsic value
6%
Share price is NT$81.8 vs Future cash flow value of NT$87.05
Current Discount Checks
For TTY Biopharm to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • TTY Biopharm's share price is below the future cash flow value, but not at a moderate discount (< 20%).
  • TTY Biopharm's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for TTY Biopharm's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are TTY Biopharm's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
GTSM:4105 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-09-30) in TWD NT$4.97
GTSM:4105 Share Price ** GTSM (2019-11-18) in TWD NT$81.8
Taiwan, Province of China Pharmaceuticals Industry PE Ratio Median Figure of 26 Publicly-Listed Pharmaceuticals Companies 22.23x
Taiwan, Province of China Market PE Ratio Median Figure of 1,423 Publicly-Listed Companies 16.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of TTY Biopharm.

GTSM:4105 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= GTSM:4105 Share Price ÷ EPS (both in TWD)

= 81.8 ÷ 4.97

16.47x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • TTY Biopharm is good value based on earnings compared to the TW Pharmaceuticals industry average.
  • TTY Biopharm is good value based on earnings compared to the Taiwan, Province of China market.
Price based on expected Growth
Does TTY Biopharm's expected growth come at a high price?
Raw Data
GTSM:4105 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 16.47x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
10.2%per year
Taiwan, Province of China Pharmaceuticals Industry PEG Ratio Median Figure of 5 Publicly-Listed Pharmaceuticals Companies 0.89x
Taiwan, Province of China Market PEG Ratio Median Figure of 247 Publicly-Listed Companies 1.07x

*Line of best fit is calculated by linear regression .

GTSM:4105 PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 16.47x ÷ 10.2%

1.62x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • TTY Biopharm is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on TTY Biopharm's assets?
Raw Data
GTSM:4105 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-09-30) in TWD NT$22.31
GTSM:4105 Share Price * GTSM (2019-11-18) in TWD NT$81.8
Taiwan, Province of China Pharmaceuticals Industry PB Ratio Median Figure of 45 Publicly-Listed Pharmaceuticals Companies 2.17x
Taiwan, Province of China Market PB Ratio Median Figure of 1,936 Publicly-Listed Companies 1.44x
GTSM:4105 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= GTSM:4105 Share Price ÷ Book Value per Share (both in TWD)

= 81.8 ÷ 22.31

3.67x

* Primary Listing of TTY Biopharm.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • TTY Biopharm is overvalued based on assets compared to the TW Pharmaceuticals industry average.
X
Value checks
We assess TTY Biopharm's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. TTY Biopharm has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is TTY Biopharm expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
10.2%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is TTY Biopharm expected to grow at an attractive rate?
  • TTY Biopharm's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • TTY Biopharm's earnings growth is positive but not above the Taiwan, Province of China market average.
  • TTY Biopharm's revenue growth is positive but not above the Taiwan, Province of China market average.
Annual Growth Rates Comparison
Raw Data
GTSM:4105 Future Growth Rates Data Sources
Data Point Source Value (per year)
GTSM:4105 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts 10.2%
GTSM:4105 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 7.7%
Taiwan, Province of China Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 11.8%
Taiwan, Province of China Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 20.2%
Taiwan, Province of China Market Earnings Growth Rate Market Cap Weighted Average 11.4%
Taiwan, Province of China Market Revenue Growth Rate Market Cap Weighted Average 8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
GTSM:4105 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in TWD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
GTSM:4105 Future Estimates Data
Date (Data in TWD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-12-31 5,159 1,441 1
2020-12-31 4,988 1,094 1,327 2
2019-12-31 4,457 1,264 1,127 2
2019-11-18
GTSM:4105 Past Financials Data
Date (Data in TWD Millions) Revenue Cash Flow Net Income *
2019-09-30 4,447 1,298 1,236
2019-06-30 4,204 980 1,263
2019-03-31 4,110 893 1,499
2018-12-31 4,036 1,074 1,461
2018-09-30 4,102 1,013 1,696
2018-06-30 4,240 1,099 1,631
2018-03-31 4,173 1,237 1,379
2017-12-31 4,079 997 1,345
2017-09-30 3,874 980 1,088
2017-06-30 3,765 1,031 1,023
2017-03-31 3,795 1,109 1,134
2016-12-31 3,761 1,227 1,193

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • TTY Biopharm's earnings are expected to grow by 10.2% yearly, however this is not considered high growth (20% yearly).
  • TTY Biopharm's revenue is expected to grow by 7.7% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
GTSM:4105 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from TTY Biopharm Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

GTSM:4105 Future Estimates Data
Date (Data in TWD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-12-31 5.80 5.80 5.80 1.00
2020-12-31 5.34 5.43 5.24 2.00
2019-12-31 4.53 4.59 4.48 2.00
2019-11-18
GTSM:4105 Past Financials Data
Date (Data in TWD Millions) EPS *
2019-09-30 4.97
2019-06-30 5.08
2019-03-31 6.03
2018-12-31 5.88
2018-09-30 6.82
2018-06-30 6.56
2018-03-31 5.55
2017-12-31 5.41
2017-09-30 4.38
2017-06-30 4.11
2017-03-31 4.56
2016-12-31 4.80

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • TTY Biopharm is expected to efficiently use shareholders’ funds in the future (Return on Equity greater than 20%).
X
Future performance checks
We assess TTY Biopharm's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Taiwan, Province of China market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Taiwan, Province of China market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
TTY Biopharm has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has TTY Biopharm performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare TTY Biopharm's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • TTY Biopharm's year on year earnings growth rate has been positive over the past 5 years.
  • TTY Biopharm's 1-year earnings growth is negative, it can't be compared to the 5-year average.
  • TTY Biopharm's 1-year earnings growth is negative, it can't be compared to the TW Pharmaceuticals industry average.
Earnings and Revenue History
TTY Biopharm's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from TTY Biopharm Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

GTSM:4105 Past Revenue, Cash Flow and Net Income Data
Date (Data in TWD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-09-30 4,446.93 1,236.08 1,299.19 320.37
2019-06-30 4,203.90 1,262.97 1,264.31 324.06
2019-03-31 4,110.35 1,499.22 1,252.79 358.17
2018-12-31 4,036.20 1,461.38 1,242.44 361.06
2018-09-30 4,101.84 1,696.16 1,224.66 332.04
2018-06-30 4,240.01 1,630.91 1,209.98 331.46
2018-03-31 4,172.81 1,379.47 1,161.00 294.09
2017-12-31 4,078.76 1,344.73 1,116.18 295.68
2017-09-30 3,874.08 1,087.88 1,097.00 321.69
2017-06-30 3,764.70 1,022.53 1,078.60 320.58
2017-03-31 3,794.52 1,133.89 1,063.37 339.72
2016-12-31 3,760.72 1,193.32 1,037.85 341.69
2016-09-30 3,733.30 1,535.67 1,055.29 354.42
2016-06-30 3,612.15 1,565.45 1,034.95 337.29
2016-03-31 3,388.69 1,393.16 1,047.70 316.70
2015-12-31 3,195.22 1,211.02 1,053.07 340.29
2015-09-30 3,057.82 1,132.62 1,060.03 327.73
2015-06-30 2,929.48 986.13 1,079.96 347.72
2015-03-31 2,968.84 828.86 1,132.14 369.64
2014-12-31 2,979.90 779.65 1,191.43 369.41
2014-09-30 2,976.04 195.78 1,233.66 394.26
2014-06-30 2,994.96 94.04 1,312.20 399.73
2014-03-31 2,956.86 124.23 1,314.78 389.68
2013-12-31 3,110.09 587.44 1,325.47 383.88
2013-09-30 3,261.65 702.00 1,341.31 392.45
2013-06-30 3,441.94 711.39 1,329.94 403.30
2013-03-31 3,876.05 917.58 1,406.60 443.21
2012-12-31 4,016.02 536.70 1,412.84 451.25

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • TTY Biopharm has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).
  • TTY Biopharm used its assets more efficiently than the TW Pharmaceuticals industry average last year based on Return on Assets.
  • TTY Biopharm has improved its use of capital last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess TTY Biopharm's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
TTY Biopharm has a total score of 4/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is TTY Biopharm's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up TTY Biopharm's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • TTY Biopharm is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • TTY Biopharm's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of TTY Biopharm's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 2.3x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from TTY Biopharm Company Filings, last reported 1 month ago.

GTSM:4105 Past Debt and Equity Data
Date (Data in TWD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-09-30 6,135.78 2,100.00 2,839.75
2019-06-30 5,833.87 1,050.00 2,804.41
2019-03-31 6,729.15 1,300.00 2,892.67
2018-12-31 6,391.63 1,500.00 2,903.13
2018-09-30 6,077.37 1,800.00 2,859.01
2018-06-30 5,769.83 1,315.23 1,794.65
2018-03-31 6,432.49 1,600.00 3,108.58
2017-12-31 6,111.64 2,200.00 3,213.13
2017-09-30 5,573.44 2,780.00 3,296.45
2017-06-30 5,282.65 1,980.00 3,337.12
2017-03-31 6,117.32 1,979.00 3,131.64
2016-12-31 6,010.31 2,079.01 3,165.26
2016-09-30 5,549.33 2,324.01 3,074.91
2016-06-30 5,348.42 1,699.01 3,152.70
2016-03-31 5,877.44 1,600.00 2,750.45
2015-12-31 5,694.95 1,900.00 2,201.07
2015-09-30 4,757.15 2,200.00 1,344.30
2015-06-30 4,261.80 1,599.99 1,422.58
2015-03-31 4,739.81 1,740.00 1,394.22
2014-12-31 4,632.44 1,740.00 1,344.18
2014-09-30 4,031.33 2,285.00 1,267.34
2014-06-30 3,903.52 1,835.00 1,381.92
2014-03-31 4,389.52 1,700.00 1,358.08
2013-12-31 4,327.72 1,600.00 1,423.00
2013-09-30 4,237.64 1,405.00 1,587.69
2013-06-30 4,230.84 1,105.00 1,566.47
2013-03-31 4,493.19 1,505.00 2,091.47
2012-12-31 4,413.04 1,495.00 1,579.21
  • TTY Biopharm's level of debt (34.2%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (56.4% vs 34.2% today).
  • Debt is well covered by operating cash flow (61.8%, greater than 20% of total debt).
  • TTY Biopharm earns more interest than it pays, coverage of interest payments is not a concern.
X
Financial health checks
We assess TTY Biopharm's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. TTY Biopharm has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is TTY Biopharm's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
5.5%
Current annual income from TTY Biopharm dividends. Estimated to be 5.07% next year.
If you bought NT$2,000 of TTY Biopharm shares you are expected to receive NT$110 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • TTY Biopharm's pays a higher dividend yield than the bottom 25% of dividend payers in Taiwan, Province of China (2.57%).
  • TTY Biopharm's dividend is below the markets top 25% of dividend payers in Taiwan, Province of China (5.93%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
GTSM:4105 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Taiwan, Province of China Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 23 Stocks 2.8%
Taiwan, Province of China Market Average Dividend Yield Market Cap Weighted Average of 1323 Stocks 4.1%
Taiwan, Province of China Minimum Threshold Dividend Yield 10th Percentile 1.4%
Taiwan, Province of China Bottom 25% Dividend Yield 25th Percentile 2.6%
Taiwan, Province of China Top 25% Dividend Yield 75th Percentile 5.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

GTSM:4105 Future Dividends Estimate Data
Date (Data in NT$) Dividend per Share (annual) Avg. No. Analysts
2021-12-31 4.78 2.00
2020-12-31 4.27 3.00
2019-12-31 3.62 3.00
2019-11-18
GTSM:4105 Past Annualized Dividends Data
Date (Data in NT$) Dividend per share (annual) Avg. Yield (%)
2019-03-26 4.500 5.546
2018-05-15 4.500 5.263
2018-03-31 4.500 4.474
2017-05-15 3.800 3.907
2017-03-29 3.800 3.723
2016-05-12 3.500 3.180
2016-03-31 3.500 3.237
2015-05-14 2.500 2.709
2015-03-30 2.500 3.699
2014-05-14 1.874 2.730
2014-03-28 1.874 2.060
2013-03-28 1.205 1.323
2012-04-30 0.208 0.243
2012-04-02 0.208 0.268
2011-04-21 0.146 0.199

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Whilst dividend payments have been stable, TTY Biopharm has been paying a dividend for less than 10 years.
  • Dividend payments have increased, but TTY Biopharm only paid a dividend in the past 9 years.
Current Payout to shareholders
What portion of TTY Biopharm's earnings are paid to the shareholders as a dividend.
  • Dividends paid are not well covered by earnings (1.1x coverage).
Future Payout to shareholders
  • Dividends after 3 years are expected to be covered by earnings (1.3x coverage).
X
Income/ dividend checks
We assess TTY Biopharm's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.4%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can TTY Biopharm afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. TTY Biopharm has a total score of 2/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of TTY Biopharm's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
  • TTY Biopharm has no CEO, or we have no data on them.
Management Team Tenure

Average tenure of the TTY Biopharm management team in years:

4.3
Average Tenure
  • The tenure for the TTY Biopharm management team is about average.
Management Team

Kuo-Chiang Chang

TITLE
Senior VP
TENURE
3.9 yrs

Shu-Wen Wang

TITLE
Accounting Officer
TENURE
4.3 yrs

Jimmy Chang

TITLE
Vice General Manager of Administration Center

Jin-Rong Lin

TITLE
Senior Vice President of Legal

Si-Yuan Yang

TITLE
Senior Vice President
TENURE
10.5 yrs

Allen Chu

TITLE
Head of Intensive Care Business Unit
Board of Directors Tenure

Average tenure of the TTY Biopharm board of directors in years:

3.4
Average Tenure
  • The tenure for the TTY Biopharm board of directors is about average.
Board of Directors

Chuan Lin

TITLE
Chairman
TENURE
1.8 yrs

Wen-Hwa Chang

TITLE
Vice Chairman
TENURE
3.3 yrs

Duei Tsai

TITLE
Independent Director
TENURE
3.4 yrs

Ming-Ling Hsueh

TITLE
Independent Director
TENURE
3.4 yrs

Hsiu-Chi Chang

TITLE
Director
TENURE
3.4 yrs

Ying-Ying Liao

TITLE
Director
TENURE
3.4 yrs

Tze-Kaing Yang

TITLE
Director
AGE
64
TENURE
3.4 yrs

Tien-Fu Ling

TITLE
Independent Director
TENURE
3.4 yrs

Carl Hsiao

TITLE
Director
TENURE
0.7 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (NT$) Value (NT$)
X
Management checks
We assess TTY Biopharm's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. TTY Biopharm has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

TTY Biopharm Company Limited, together with its subsidiaries, produces various pharmaceuticals and chemical drugs in Taiwan and internationally. It offers oncology and anti-infection drugs; and gastro-intestinal, bone, and metabolic healthcare products, as well as products for cardiovascular diseases. The company was founded in 1960 and is headquartered in Taipei City, Taiwan.

Details
Name: TTY Biopharm Company Limited
4105
Exchange: GTSM
Founded: 1960
NT$20,339,570,000
248,650,000
Website: http://eng.tty.com.tw/
Address: TTY Biopharm Company Limited
No.3-1, Park Street,
3rd Floor,
Taipei City,
11503,
Taiwan
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
GTSM 4105 Common Stock Taipei Exchange TW TWD 05. Oct 2001
Number of employees
Current staff
Staff numbers
0
TTY Biopharm employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/11/18 14:58
End of day share price update: 2019/11/18 00:00
Last estimates confirmation: 2019/11/17
Last earnings filing: 2019/11/12
Last earnings reported: 2019/09/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.